Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study

BACKGROUND: Nearly 50% of breast cancer patients suffer from depression or anxiety. Selective serotonin reuptake inhibitors (SSRIs), the first-line pharmacological treatment for depression, have been implicated in breast cancer development through increased prolactin levels and tamoxifen metabolism...

Descripción completa

Detalles Bibliográficos
Autores principales: Busby, John, Mills, Ken, Zhang, Shu-Dong, Liberante, Fabio Giuseppe, Cardwell, Chris R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775583/
https://www.ncbi.nlm.nih.gov/pubmed/29351761
http://dx.doi.org/10.1186/s13058-017-0928-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775583/
https://www.ncbi.nlm.nih.gov/pubmed/29351761
http://dx.doi.org/10.1186/s13058-017-0928-0

Ejemplares similares